At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology. By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals. Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses. Sometimes it requires investing in publicly-traded companies.
Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.
An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.
The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.
The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money. It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.
Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone. This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

1,195 patients with prostate cancer participated in the study. The patients had already their treatment with one or several chemotherapy regimens, which had little effect on their disease. According to the data revealed at the European Society for Medical Oncology meeting that took place in Milan, abirateroneacetate taken along with the steroid prednisone, increased survival rate in patients by median 3.9 months if compared with those patients, who received prednisone alone.

This was the third stage of the trial, which is the last stage before a drug goes under regulatory approval by FDA. With its headquarters in New Brunswick, NJ, Johnson & Johnson is going to file an application for abiraterone approval by the U.S. and European drug administration councils. This application is a reasonable step after such promising results of the drug’s trial and according to the statement by J&J, they will file the new-drug application by the end of the year.

According to Larry Biegelsen, an analyst working at Wells Fargo Securities, NY, abiraterone represents a nearly billion dollar chance for those suffering advanced metastatic prostate cancer.

In July 2009, the drug was acquired by Johnson & Johnson for $878 million from Cougar Biotechnology, one of the many portfolio companies of Dr. Lindsay Rosenwald. Dr. Rosenwald is one of the most prolific entrepreneurs and financial investors in the field of biotechnology. He supports new research, development of novel drugs and prospective biotechnology candidates that may help medicine broaden its horizons and provide more benefit to humanity. Lindsey Rosenwalds latest investments in Cougar Biotechnology and their prostate cancer drug, abiraterone acetate, are thought to be the beneficial for all prostate cancer patients since the drug demonstrates its ability to stop tumor cells from generating excess testosterone, a male hormone, which is needed to reproduce and give life to new tumor cells.

According to statistics by the National Cancer Institute, this year more than 217 thousand men in the U.S. will have prostate cancer diagnosed by their doctors, and more than 32 thousand men will die of the disease. The American Cancer Society had recently revealed the data showing that prostate cancer takes the second place of cancer deaths in men, after lung cancer.

Having seeing promising results in patients taking abiraterone acetate, Johnson & Johnson decided to un-blind the trial and give other patients the ability to try abiraterone. This decision was led by an interim analysis data, which showed that the drug extended lives and had a good safety profile.

Additional Couple of Months

Those patients, who took abiraterone acetate, had much decreased tumor progression rate if compared with those taking the steroid prednisone. They lived two months longer and their median survival was about 15 months, while those in the prednisone group lived about 10 months. Among the side effects noticed during the intake of abiraterone are: fluid retention, heart disorders, low potassium in the blood.

The placebo group in the J&J trial was offered abiraterone. There is also a program that J&J is going to implement – to provide access to the drug to other patients meeting certain criteria. The drug will be distributed by Ortho Biotech Oncology Research & Development, which is a subsidiary of J&J, by the end of the year.

According to Howard Scher, at Kettering Cancer Center, NY, and Lindsay Rosenwald, MD, the owner of BioSciences and biotechnology investment banks, the abiraterone treatment is very beneficial, especially for those patients who had little or no treatment options when their disease took a massive scale.

It is only the matter of time to understand why some men have a good response to abiraterone acetate while others don’t have this positive effect.

Another Prostate Cancer Drug, Provenge

An alternative treatment for metastatic prostate cancer, Provenge by Dendreon Corp, is known to help patients extend lives to median 4 months. It is very difficult to compare these two drugs, because abiraterone was tested in patients with a more aggressive cancer stage that failed even after at least 1 chemotherapy regimen. During the Provenge trial, patients lived about 21 months.

Provenge represents the 1^st drug developed to support the immune system and help it fight cancer. In April 2010, the drug was approved by FDA and now it can be bought for about $93 thousand for 3 doses, while abiraterone is expected to be sold for $27 thousand.

According to an analyst in Deutsche Bank Equity Research, Robyn Kanrauskas, and Dr. Lindsay Rosenwald, a key investor in the biotechnology sector, as for now, both drugs look very promising and will have room for further development and improvement.

The COU-AA-301 randomized, placebo-controlled trial involved 1,195 patients with castrate-resistant prostate cancer (another name for metastatic advanced prostate cancer). The disease progressed after receiving chemotherapy based on Taxotere (docetaxel). One group of 797 men was treated with abiraterone acetate plus low-dose prednisone, and another group of 398 patients was treated with placebo plus prednisone/prednisolone. The abiraterone group demonstrated increased median survival to 14.8 months compared to 10.9 of the placebo group. Although 3.9 months seems not very much, but according to Lindsay Rosenwald and Johann de Bono, only four drugs in the history of prostate cancer had survival benefit; and abiraterone is likely to bring the change to the lives of patients with advanced prostate cancer.

36 percent of patients treated with abiraterone acetate had median survival and 35 percent had fatal outcome risks compared with patients in the placebo group. Furthermore, patients, who received abiraterone had significant improvement in secondary endpoints, including TTPP or time to PSA progression as well as RPFS or radiographic progression-free survival.

In September 2010, when the trial data demonstrated significant survival improvement, the analysts recommended that the patients treated with placebo in the Phase III study should be offered abiraterone acetate. In late 2010, Johnson & Johnson filed marketing applications for the approval of abiraterone acetate. If approved by FDA, the drug will be distributed in the U.S. and Europe by mid-2011; and then will follow in the rest of the world according to local regulations. Lindsay Rosenwald, MD, one of the lead investors in the biotechnology sector, noted that abiraterone acetate could become a very promising candidate that can bring difference to patients with advanced prostate cancer.

There are many portfolio companies involved in the drug research. There is a separate company which is intended for the co-ordination and facilitation of drug development and drug research in these companies, which are founded by Dr. Lindsay Rosenwald. It is also involved in the general corporate development of the portfolio companies of the group.  Another group is a multi national company. This health care investment company concentrates on the concepts that produce new drugs and also the companies which try to produce them. The main of this company is to provide support to these sprouting new companies. It is crucial in finding the financial support to the portfolio companies. Bio Capital is a broker dealer company that has a valid registration. It is registered with Financial Industry Regulatory Authority which is usually abbreviated as FINRA. The success of Bio Capital Company can be known by looking at the statistics of the company and the fund raised by the company. Till now, the company has raised a whooping amount of nine hundred and fifty million dollars for the development of portfolio companies. All these companies are initiated by Rosenwald. When coming to the life story of Rosenwald, he has done his schooling in Pennsylvania till the year 1973. Then he wanted to join in finance course at masters’ level. So, he moved to Pennsylvania State University. He has completed his graduation in Beta Sigma Gamma in the year 1977. Then he took up medicine studies at Temple University’s school of medicine. After completing his medicine studies in 1983 he joined his internship in Abington Medical Hospital. At the same time, he has started his own practice.

Lindsay Rosenwald has a passion towards finance field and it has led him to move to Wall Street. There he emerged in to a unique person by taking two professions at the same time. They are medical practitioner and analyst.  It is a unique kind of job where he is the first of his kind. Rosenwald got fame in both the professions and he is considered as legend in associating bio technology and life sciences with financial world. His initiations has now seen in the form of bigger companies which are considered as pioneer in their respective fields.

In pursuit of his lifelong wish, Lindsay Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before beginning his own private practice. After filling out his internship, he functioned as a medical professional in his private practice for 2.5 years. Though he liked practicing medicine Dr. Rosenwald sensed as if something was absent. He made the decision he needed to combine his 2 interests, business enterprise and medical science, and look for a career that would let him pursue those passions.

Lindsay Rosenwald eventually left his private practice in 1986 to go to Wall Street where he got on a position as a Physician / Analyst, an extremely exclusive placement with just a few people doing it at that time. In spite of the belief that doctors don’t make good investors, Dr Rosenwald excelled at this job. He worked here because he felt it was vital to focus on opportunities in the medicine and health sector. He received superb respect in his brand new position, and although he missed his old private practice, he knew this is where he truly belonged. He also worked for an exclusive investment company, DH Blair Co as the Controlling Director of Finance, but left after a few years to concentrate on a brand new enterprise.

With time, he has widened this company by establishing new companies and gaining control of other biotech firms. The business has financed more than two dozen businesses in the last three years. He is able to make these acquired companies successful because he focuses on both improving the corporate framework of the organization. All of these companies are separate entities, but interact to aid each other. The businesses that Rosenwald handles have licensed or obtained over a hundred experimental stage medicines.

Possibly one of Dr Rosenwald’s greatest accomplishments is that he set the record for the fastest development of a drug. In only thirty months, Arsenic Trioxide was developed and approved by the FDA for treating a deadly type of the leukemia disease. This medicine has been on the market worldwide for more than ten years and it has saved and extended 1000s of lives.

Rosenwald has been revolutionary with the firms he has created. One of his businesses sold to J&J for over One Billion Dollars despite the fact that they only had one medicine with phase 2 data. He is also the cause of bringing a stem cell business, a cancer vaccine organization, and a gene therapy company all to market. As Rosenwald as the leader, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his achievements he created the first successful medicine to assist those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is he employs PHDs, MDs, MBAs, and other experts to function as his senior level professionals. These people provide plenty of experience in both the medical and business arenas that will help make his businesses more powerful and more diverse. They are driven to create new medicines as fast as possible. A few of these drugs have the potential to alter the way we view medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to medical and science instruction to help create the future of medicine.

Lots of people credit the success of the biotech industry on a whole to Dr. Lindsay Rosenwald. His visionary companies have altered many lives and made Dr. Rosenwald’s personal assets soar to the tune of $600 million.

Michael Brush, a New York financial writer and a member of editorial staff at MSN Money, mentions Dr. Lindsay Rosenwald, among other venture capitalists. In his article, called “Company Focus. 4 picks from all-star insiders”, Brush writes about how the purchase of two biotech companies, Cell Therapeutics and Neose Technologies, increased profits of Lindsay Rosenwald’s companies to 100% to 280%. The average winnings generated over the six-month period following purchase in all the trades in these two stocks were 59% and 64%, respectively. Brush also writes about another biotech company, called Genta that interested Dr. Rosenwald at the time.

Lindsay Rosenwald is also featured in The New York Times. In the article, “BUSINESS PEOPLE; D.H. Blair Picks Doctor As Director of Finance”, Dr. Rosenwald’s path from the doctor’s office to the investment bank is described. After finishing college at Penn State, Lindsay Rosenwald was torn about what career to pursue. He was very good in finance and economics at Penn State, but he really wanted to be a doctor. This led him to the medical school at Temple University, where Rosenwald did consulting for health-care companies and managed money for physicians and his professors. For two years and a half had Dr. Rosenwald been involved into private practice, although he was lured to Wall Street, where he finally got to as a securities analyst. In a year, D.H. Blair assigned Rosenwald as Director of Finance in the premier firm on the Wall Street.

In an article at the online edition of Temple Times, Dr. Lindsay Rosenwald is mentioned among other prominent venture capitalists and employees in big corporations, who took off their medical degree for the world of business and finance. Lindsay Rosenwald is the most notable person in biotechnology financing sector. With offices on three continents, the company specializes in asset management, investment banking, and direct investing in the biotech and life-sciences industries.

Another coverage of the results of Dr. Lindsay Rosenwald’s activities can be found in the Reverse Merger book by David Feldman, one of the country’s leading experts on reverse mergers. In his blog Reverse Merger & SPAC Blog, you can find a short abstract from his book devoted to one of the biotechnology firms funded by Lindsay A. Rosenwald: As reported in the Reverse Merger Report, Cougar Biotechnology was sold in 2009 to Johnson & Johnson for $1 billion. The amount was really impressive! After Cougar was reverse merged with a Form 10 shell, its stock price had risen 145%, and this was one of the most successful reverse mergers in the history.

He is also the founder of various companies include Biocryst Pharmaceuticals, Titan Pharmaceuticals, Cypress Biosciences, Keryx Biopharmaceuticals, Javelin Pharmaceuticals, Polarx; and Enzymed Corp. Most of these companies are involved in drug development and advanced clinical research. In addition to this, he is one of the advisory members of advisory board of Columbia-Presbyterian Health Sciences and Advisory Counsel, which is a group that felicitates people who have done extensive research in the biotechnology industry. Dr. Lindsay Rosenwald has been serving as one of the director of several public and private limited companies around the world. The famous company, Cougar Biotechnologies has bee sold out to Johnson and Johnson for a whooping price of nearly one billion dollars. This is one of the best deals in the biotechnology market. Most of the drugs developed by the companies get the FDA approvals with in a short span of time. All these companies have been growing at good rate under the dynamic leadership of Rosenwald.

In an online article that was posted on the MSN Money page, in the Investing section, Michael Brush describes the best way to achieve success with your investing. In 4 Picks From All-Star Insiders, Michael tells his readers about how the best way for an individual investor, such as Lindsay Rosenwald, to make money in the market is to find, follow, and mimic the most successful insiders. He also states that some insiders are better than others at knowing how to successfully navigate within the stock market game. He then goes on to name some of the top players who have some of the best stats and success in generating dollars from their investing activities.

Among the people he names as a big winner, he presents Dr. Lindsay Rosenwald as the absolute best of them all. Dr. Rosenwald has made large sums of money while operating as a hedge fund manager and venture capitalist who is based in New York. Michael Brush is quick to tell of how Lindsay Rosenwald was able to amass large profits ranging from  100% to 280%. This was done over done over the course of a six month period, after the well timed purchase of two biotech companies named Cell Therapeutics and Neose Technologies. In addition to that the average gain for each trade he made in the stocks of these two companies is 59% for Cell Therapeutics and 64% for Neose Technologies.

As stated by Michael Brush in this article, Lindsay Rosenwald has developed a great reputation as a person who really knows how to spot a winning trade. Lon Gerber, who happens to be an insider expert for Thomson Financial, says that Dr. Rosenwald’s returns are incredible. Furthermore, as far as the consistency of his success, Lindsay Rosenwald has managed to create a broad record of creating successful bio-tech investments over the course of several years.

New York Times Article

In the online article titled BUSINESS PEOPLE; D.H. Blair Picks Doctor As Director of Finance, Daniel F. Cuff of The New York Times describes Dr. Lindsay Rosenwald as one of the few exceptions to the Wall Street truisms which states that doctors tend to make for bad investors. This is made evident with his appointment as managing director in corporate finance for a Wall Street firm named D.H. Blair & Company.

The article then goes on to tell about Dr. Rosenwald’s earlier life and past history. Lindsay Rosenwald, who is originally a native of Philadelphia, was very conflicted as to what career he should choose. He had already finished college and attained a degree in Finance from Penn State, but he also had a strong interest in the medical field and desired to practice as a doctor. This is the reason why he soon chose to enroll in Temple University’s school of medicine.

Even during the time of his medical training and practice, he still made use of his financial knowledge and skills by managing money for his professors and various physicians. He also did some consultation work for health-care companies. Finally, even after having establishing his own medical practice, Dr. Rosenwald decided to give in to the call of Wall Street that was again urging him to pursue work in the financial world.

Daniel F. Cuff then explains how Lindsay Rosenwald combined his knowledge of finance and medicine in order to gain a unique edge when dealing with financial markets. Dr. Rosenwald went to New York in order to work as a securities analyst. Eventually, he got married and started a family, settling down in Manhattan. He also began spending his time looking for and investing in start-up biotech companies that have the potential to make money. The companies he has worked with include names such as Molecular Biosystems, Organogenesis and Marrow Tech.

Cougar Biotech Blog

Cougar Biotech – Wow! is an article that was written by David Feldman and deals with a topic related to finance. Specifically, it talks about a man named Dr. Lindsay Rosenwald and the company named Cougar Biotechnology. David Feldman starts out by highlighting the successful selling of Cougar Biotechnology to Johnson & Johnson for an offer of $1 billion. He also notes that Cougar Biotechnology is backed by none other than Dr. Lindsay Rosenwald himself. David also tells of how Cougar Biotechnology reverse merged with a Form 10 shell that was affiliated by Richard Rappaport’s WestPark Capital in LA, back in 2006.

David Feldman says that the stock price of Cougar Biotechnology rose by 145% since the time when it began to trade after the very beneficial reverse merger. The pre-arranged financing of Cougar Biotechnology was set at an incredibly high dollar amount for its time and even for now today. This totaled 50 million and took place during the time of the reverse merger. The article goes on to state that this reverse merger of a company backed by Dr. Rosenwald can be put on the list of the most successful reverse mergers ever. He also compares the success of the merger to others such as Texas Instruments, Blockbuster Entertainment, Berkshire Hathaway, Occidental Petroleum, Tandy Corp. (Radio Shack), and Turner Broadcasting just to name a few.

Below this article, a comment from a reader, made on February 7, 2010, goes on to explain some of the other accomplishments of Dr. Lindsay Rosenwald. Namely, stating how his various contributions to the world of medical research and the biomedicine field has been of a huge benefit to many. Jake Wilson then states that Dr. Rosenwald’s contributions mainly originate from the group of companies for which the doctor himself is the Founder and Chairman. After that there is mention of how the companies are actively involved in things such as facilitating and coordinating research, corporate development, global investing and development, and the support of biotech companies that are new to the arena business.

Temple Times & Lindsay Rosenwald

Giselle Zayon has created a rather informative article for the online edition of Temple Times. The title of that article is Dual degree helps Medical School graduates take on business world and it speaks about how Dr. Lindsay Rosenwald, a trained medical doctor as well as a financial guru, has combined both his knowledge and unique talents in order to operate as a strong force in the financial world. Giselle describes Lindsay Rosenwald as definitely being the person you want to see if you wish to learn more about biotechnologies and emerging drugs, even if the doctor no longer chooses to practice as a medical physician.

Dr. Rosenwald seems to be a man that was born to make money and be a key player in the financial world. In the article, Giselle Zayon goes on to quote Dr. Lindsay Rosenwald telling of how he manages investor assets, works with private equity, both offshore and domestic hedge funds, invests in both public and private turnaround and start-up companies, and makes placement offerings for certain biotech companies.

The doctor originally studied and attained a degree for finance and economics at Penn State University before taking up medical studies at Temple. A short time after also completing his medical school training, internship, and even establishing his own practice, Lindsay Rosenwald decided to return to the world of finances.

Rosenwald’s foundation is one which develops the Biotechnology field and increases the investment bank. This is the organization under which numbers of researchers grouped into teams strived hard to start a company and were successful by reaching to certain low height. Though this is a small measure was good at its initial stages.

The teams help the companies to handle the drug development. The team mainly is formed by the members like managing directors, Ph Ds, legal representatives, accounts, drug developers and many more who are highly qualified according to their positions in the companies who are authorized by their superiors and are given by the objectives to fulfill their jobs to make the company reach the goals.

Silhouette of Dr. Lindsay Rosenwald includes general practitioner and economic analysis which was one of the difficult tasks to be taken into control by few people who are mastered in these issues. This helps Rosenwald to launch few more companies which are related to the fields of Biotechnology and Life Sciences.

Dr. Lindsay Rosenwald received his education from Pennsylvania and obtained graduation from schooling in the year nineteen seventy three. He then joined Abington High School to study and then after that joined Pennsylvania State University to complete his course related to Finance and Economy. Where he become chief in these fields in the year nineteen seventy seven and was tribute with Beta Gamma Sigma. He worked has a specialist for few years in the health care corporations and then went to Temple University’s School of Medicine in the year nineteen eighty three to complete his medicine.

Dr. Lindsay Rosenwald practiced his initial private enterprise scheme when he declared to be eligible to perform as a physician. He then moved to New York after practicing there for few more years and dedicating to many of the fields in various forms. All his dedications were to the development and improvements to the fields of Biotechnology.